ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This double-blind, multicenter trial randomized 328 children and adolescents (8-17 years-old) diagnosed with type 1 diabetes (T1D) within the past 6 weeks to receive either teplizumab or placebo for two 12-day courses. Teplizumab increased stimulated C-peptide levels after 1.5 years, indicating better preservation of β-cell function.Teplizumab is a monoclonal antibody that binds to CD3 on the surface of T-cells, thereby reducing the i...

Brief summary: In this longitudinal study, blood glucose trajectories and their relationship with autoantibodies appearance were assessed in 1050 children with high genetic risk of type 1 diabetes (T1D) between 4 months and 3.6 years. Post-prandial blood glucose levels increased around 2 months prior to autoantibody seroconversion, with further increases thereafter, suggesting that islet autoimmunity co-occurs or follows insults on the β-cells.This ...